ArticleCureus2025

Effect of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors on Lipid Profile and Cardiovascular Events in High-Risk Diabetic Patients.

Vasavi Patra et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.